Philadelphia, PA (July 30, 2019) – Oncoceutics, Inc. announced that a series of presentations at the 2019 DIPG/DMG Symposium to be held August 2-3 in Sydney, Australia, will highlight ONC201 as a promising treatment for specific types of lethal brain cancer. These presentations are part of a session describing progress in new drug development for
Philadelphia, PA (July 23, 2019) – Oncoceutics, Inc., announced a collaboration with the National Cancer Institute (NCI) funded Pediatric Preclinical Testing Consortium (PPTC) to enable tumor type selection for ONC201 clinical trials in pediatric oncology beyond diffuse midline gliomas. The PPTC program addresses key challenges associated with the development of new therapies for children with
Philadelphia, PA (July 17, 2019) – Oncoceutics, Inc. issues this announcement on Glioblastoma Awareness Day to reiterate its support for all those suffering from, or broadly affected by, gliomas. A bipartisan resolution, Senate Resolution 245, introduced on May 16, 2019, by U.S. Senator Lindsey Graham (R-SC), with the support of Senators Mitch McConnell (R-KY), Elizabeth
Philadelphia, PA (July 1, 2019) – Oncoceutics, Inc. announced a scientific publication in the journal Leukemiademonstrating selective and potent agonism of the G-protein coupled receptor (GPCR) GPR132 by ONC212, an imipridone derivative of ONC201. GPR132 is an orphan GPCR previously shown to play a tumor suppressor role in acute leukemias that has not been targeted
Business Development